Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in <i>EGFR</i> Wild-type Cancers

Abstract

Amphiregulin expression may help select EGFR wild-type patients who are likely to develop stable disease from EGFR-targeted therapies.